Navigation Links
Resolve Initiates Phase 2 Clinical Study in SLE
Date:7/16/2014

SEATTLE, July 16, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of a multi-dose, one month phase 2 clinical study with its lead compound RSLV-132 in systemic lupus erythematosus (SLE).

Following the successful completion of it phase 1 single dose safety study with RSLV-132, Resolve recently initiated a phase 2 study in lupus patients.  The study will be conducted at multiple sites in the U.S., and will investigate four dose levels, with multiple doses being administered over one month.  The study is designed to establish biological proof-of-concept for RSLV-132.

RSLV-132 is a novel Fc fusion protein consisting of human RNase attached to the Fc portion of human IgG.  The goal of the therapy is to reduce the burden of circulating RNA-containing immune complexes which are thought to be the most proximal trigger of the systemic inflammation characteristic of SLE.  By eliminating the RNA cargo contained in circulating immune complexes the therapy is designed to prevent chronic activation of nucleic acid sensing toll like receptors (e.g. TLR7 and TLR8) and subsequent activation of the interferon inflammatory cascade.  Additional therapeutic benefit is thought to result from dampening B-cell activation, as well as mitigation of the direct tissue damage caused by immune complex deposition in key organs, such as the kidney and brain.

"We are thrilled to move RSLV-132 one step closer to the large number of SLE patients that are not well controlled with current therapy" commented James Posada, chief executive officer of Resolve Therapeutics.

About Resolve Therapeutics
Resolve Therapeutics is a privately held biotechnology company based in Seattle that is dedicated to helping patients with lupus through the development of its platform of targeted nuclease therapeutics.  In addition to the lead molecule, RSLV-132, the company is developing additional molecules that contain both RNase and DNase activities, which may also be useful in the treatment of lupus and other autoimmune diseases resulting from aberrant nucleic acid deposition.  Resolve is funded by a syndicate of venture capital firms including, New Science Ventures, WRF Capital, and Easton Capital.  For more information on the company please visit us at:  http://www.resolvebio.com

Contact:

James Posada, Ph.D., MBA
Chief Executive Officer
Resolve Therapeutics, LLC
(208) 876-4057
jp@resolvebio.com

Logo - http://photos.prnewswire.com/prnh/20140715/127341


'/>"/>
SOURCE Resolve Therapeutics, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. RSC New England Clinicians to Present at RESOLVE New England’s 20th Annual Conference on November 2nd, 2013
2. New nanomedicine resolves inflammation, promotes tissue healing
3. WMIS Supports Experts, Commits to Resolve Beta Amyloid Issues with CMS
4. BioFit Helps Lab Specifiers Resolve to Improve Worker Safety and Productivity in 2013 through Ergonomic Seating Use
5. Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
6. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
7. inVentiv Health Initiates Refinancing Transactions To Fund Continued Growth
8. EquitiesIQ Initiates Coverage of Alliqua, Inc.
9. OxThera Initiates Clinical Trial in Primary Hyperoxaluria
10. Empire Asset Management Company initiates coverage on INSPIRE MD with a Buy rating
11. Acacia Pharma Initiates Pivotal Phase 3 Studies with APD421 in Post-Operative Nausea & Vomiting (PONV)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... ... January 19, 2017 , ... November Research Group, LLC, ... and medical device manufacturers and regulators, is proud to announce the worldwide release ... client designed to provide product vigilance departments with the flexibility and ease of ...
(Date:1/19/2017)... Jan. 19, 2017 AquaBounty Technologies, Inc. (AIM: ... productivity in aquaculture and a majority-owned subsidiary of Intrexon ... has completed the listing of its common shares on ... from Intrexon. "AquaBounty,s listing on NASDAQ represents ... our exposure to the U.S. markets as we advance ...
Breaking Biology Technology:
(Date:12/22/2016)... December 22, 2016 SuperCom (NASDAQ: ... solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced ... has been selected to implement and deploy a community-based supportive services ... Northern California , further expanding its presence in the state. ... This new program, ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):